Have a feature idea you'd love to see implemented?
Let us know!
UNCY Unicycive Therapeutics Inc
Price (delayed)
$0.53
Market cap
$55.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.74
Enterprise value
$23.47M
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic
Highlights
The company's EPS has surged by 57% YoY and by 10% QoQ
UNCY's net income is up by 18% year-on-year
UNCY's debt is up by 27% since the previous quarter but it is down by 7% year-on-year
UNCY's quick ratio is down by 3.1% since the previous quarter
Key stats
What are the main financial stats of UNCY
Market
Valuations
Earnings
Shares outstanding
103.8M
Market cap
$55.01M
Enterprise value
$23.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$22.93M
EBITDA
-$22.56M
Free cash flow
-$26.52M
Per share
Balance sheet
Liquidity
EPS
-$0.74
Free cash flow per share
-$0.3
Book value per share
$0.3
Revenue per share
$0
TBVPS
$0.43
Total assets
$38.57M
Total liabilities
$10.72M
Debt
$807,000
Equity
$27.85M
Working capital
$27.28M
Debt to equity
0.03
Current ratio
3.61
Quick ratio
3.09
Net debt/EBITDA
1.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-80.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-81.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UNCY stock price
How has the Unicycive Therapeutics stock price performed over time
Intraday
0.42%
1 week
15.22%
1 month
22.97%
1 year
-8.62%
YTD
-38.92%
QTD
29.93%
Financial performance
How have Unicycive Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.17M
Net income
-$23M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 43% YoY
UNCY's net income is up by 18% year-on-year
Growth
What is Unicycive Therapeutics's growth rate over time
Valuation
What is Unicycive Therapeutics stock price valuation
P/E
N/A
P/B
1.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 57% YoY and by 10% QoQ
Efficiency
How efficient is Unicycive Therapeutics business performance
UNCY's ROA is up by 50% YoY and by 14% QoQ
Dividends
What is UNCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UNCY.
Financial health
How did Unicycive Therapeutics financials performed over time
Unicycive Therapeutics's total assets has soared by 98% YoY but it has decreased by 14% from the previous quarter
Unicycive Therapeutics's total liabilities has decreased by 33% YoY and by 20% from the previous quarter
UNCY's debt is 97% smaller than its equity
Unicycive Therapeutics's debt to equity has surged by 175% QoQ but it has shrunk by 88% YoY
UNCY's debt is up by 27% since the previous quarter but it is down by 7% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.